Omeros (OMER) Competitors

Omeros (NASDAQ:OMER) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Does the media favor OMER or SUPN?

In the previous week, Omeros had 6 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 13 mentions for Omeros and 7 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Omeros' score of 0.46 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, OMER or SUPN?

Omeros has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Do analysts rate OMER or SUPN?

Omeros currently has a consensus target price of $22.50, indicating a potential upside of 164.08%. Supernus Pharmaceuticals has a consensus target price of $36.00, indicating a potential upside of 11.35%. Given Omeros' stronger consensus rating and higher possible upside, research analysts plainly believe Omeros is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80
Supernus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the MarketBeat Community favor OMER or SUPN?

Omeros received 269 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 72.98% of users gave Supernus Pharmaceuticals an outperform vote while only 70.87% of users gave Omeros an outperform vote.

Company	Underperform	Outperform
Omeros	Outperform Votes 747 70.87%	Underperform Votes 307 29.13%
Supernus Pharmaceuticals	Outperform Votes 478 72.98%	Underperform Votes 177 27.02%

Is OMER or SUPN more profitable?

Supernus Pharmaceuticals has a net margin of 9.16% compared to Omeros' net margin of 0.00%. Supernus Pharmaceuticals' return on equity of 7.79% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	N/A	-49.92%
Supernus Pharmaceuticals	9.16%	7.79%	5.67%

Which has preferable earnings & valuation, OMER or SUPN?

Supernus Pharmaceuticals has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$117.81M	-$2.31	-3.69
Supernus Pharmaceuticals	$661.82M	2.73	$1.32M	$1.32	24.49

Do institutionals and insiders believe in OMER or SUPN?

48.8% of Omeros shares are held by institutional investors. 12.3% of Omeros shares are held by insiders. Comparatively, 9.3% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Omeros and Supernus Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.